Meningococcal vaccine groups A B C Y W-135 conjugate - GlaxoSmithKline

Drug Profile

Meningococcal vaccine groups A B C Y W-135 conjugate - GlaxoSmithKline

Alternative Names: MenABCWY; Meningococcal ABCWY Vaccine; rMenB + MenACWY

Latest Information Update: 02 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer GlaxoSmithKline
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections

Most Recent Events

  • 26 Oct 2016 Efficacy data from a phase IIb trial in Meningococcal group B vaccine presented at IDWeek 2016 (IDW-2016)
  • 26 Oct 2016 Immunogenicity and adverse events data from a phase II trial in Meningococcal infections presented at the ID Week 2016 (IDW-2016)
  • 25 Oct 2016 GlaxoSmithKline plans a phase IIb trial for Meningococcal group A, B, C, W and Y infections (In adolescents, Prevention) in Poland and Finland (IM) (NCT02946385)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top